ArticleNature2021
Cell-programmed nutrient partitioning in the tumour microenvironment.
Open access · greenAbstract read
In one paragraph
Article in Nature, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 636 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
636citing papers in PubMed, 1 pooled it
63.3field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
636 citing papers in PubMed, 1 synthesis or guideline pooled it, 962 citations in OpenAlex.
- Immune-Based Therapies in Pancreatic Cancer: a Systematic Review of Ongoing Clinical Trials (2020-2022).Journal of gastrointestinal cancer · 2025Pooled it
- Results of the Phase I/II Study and Preliminary B-cell Gene Signature of Combined Inhibition of Glutamine Metabolism and EGFR in Colorectal Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Trial
- MITF-Driven melanoma plasticity as a core mechanism of therapy resistance: integrating microenvironmental signaling, mechanotransduction, and metabolic reprogramming.Cell cycle (Georgetown, Tex.) · 2026Review
- Metabolites and cancer metastasis.Oncogene · 2026Review
- Targeting myeloid cell plasticity and metabolic reprogramming to alleviate T cell dysfunction and exhaustion-associated states and enhance immune checkpoint blockade therapy.Biomarker research · 2026Review
- Intratumoral Fusogenic Outer Membrane Vesicles Enhance Antitumor Immunity Through Tumor MHC-I Upregulation and Tumor Bacterization.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- IL-1α Expands SLC2A1highSPP1highIFNlow Myeloid Cells to Drive Immune Escape and Malignant Transformation of Precancers.Cancer research · 2026Article
- Nanotechnology-enabled precision targeting of lung cancer stem cells: Recent developments and therapeutic implications.Stem cell reviews and reports · 2026Review
- Post‑translational modification‑governed immune states in cancer immunity: Biomarker implications for checkpoint competence, tumor visibility and immunotherapy resistance (Review).International journal of oncology · 2026Review
- Metabolic determinants of autoimmune kidney diseases.Nature reviews. Nephrology · 2026Review
- Multifocal ground-glass opacities in lung cancer: a narrative review of genomic evolution, immune ecology, and biology-informed clinical management.Journal of thoracic disease · 2026Review
- Immune-pressure redistribution in resistance to PD-1/PD-L1 blockade: mechanisms, biomarkers, and therapeutic design.Molecular cancer · 2026Review
- Drugging small-molecule compounds in autophagy-dependent cell death to overcome cancer therapy resistance.Apoptosis : an international journal on programmed cell death · 2026Review
- Macrophages transfer functional proteins to their surface during live-cell uptake.Nature chemical biology · 2026Article
- Targeting the PD-L1-induced PDK4/GLS metabolic axis overcomes anti-PD-1 resistance in non-small cell lung cancer.Journal for immunotherapy of cancer · 2026Article
- Pathophysiological roles of monocytes and macrophages in cancer.Nature reviews. Immunology · 2026Review
- Spatiotemporally reprogrammed L-arginine metabolic nanoregulator potentiates immunotherapy.Bioactive materials · 2026Article
- Spatially organized regulated cell death-immune coupling in solid tumors: integrating spatial omics with actionable regulated cell death biology.Molecular cancer · 2026Review
- N-glycans in non-malignant tumor microenvironment cells dampen CAR-T cell function in solid tumors.Journal for immunotherapy of cancer · 2026Article
- Article
576 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
32 authors at 6 institutions in 1 country.
Bradley I Reinfeld *Medical Scientist Training Program, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-4161-8301
Matthew Z Madden *Medical Scientist Training Program, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0003-4062-4427
Melissa M WolfDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Anna ChytilDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Jackie E BaderDepartment of Pathology, Microbiology and Immunology, VUMC, Nashville, TN, USA.
Andrew R PattersonDepartment of Pathology, Microbiology and Immunology, VUMC, Nashville, TN, USA.
Ayaka SugiuraMedical Scientist Training Program, Vanderbilt University, Nashville, TN, USA.
Allison S CohenDepartment of Radiology and Radiological Sciences, VUMC, Nashville, TN, USA.
Ahmed AliKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.
Brian T DoKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-4992-2623
Alexander MuirBen May Department for Cancer Research, University of Chicago, Chicago, IL, USA.
Caroline A LewisWhitehead Institute for Biomedical Research, MIT, Cambridge, MA, USA.ORCID http://orcid.org/0000-0003-1787-5084
Rachel A HongoDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Kirsten L YoungDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Rachel E BrownMedical Scientist Training Program, Vanderbilt University, Nashville, TN, USA.
Vera M ToddDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Tessa HuffstaterDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0002-7906-807X
Abin AbrahamMedical Scientist Training Program, Vanderbilt University, Nashville, TN, USA.
Richard T O'NeilDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Matthew H WilsonDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Fuxue XinDepartment of Radiology and Radiological Sciences, VUMC, Nashville, TN, USA.
M Noor TantawyDepartment of Radiology and Radiological Sciences, VUMC, Nashville, TN, USA.
W David MerrymanDepartment of Biomedical Engineering, Vanderbilt University, Nashville, TN, USA.ORCID http://orcid.org/0000-0001-9662-1503
Rachelle W JohnsonDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Christopher S WilliamsDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Emily F MasonDepartment of Pathology, Microbiology and Immunology, VUMC, Nashville, TN, USA.
Frank M MasonDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.ORCID http://orcid.org/0000-0003-1338-494X
Katherine E BeckermannDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA.
Matthew G Vander HeidenKoch Institute for Integrative Cancer Research and Department of Biology, Massachusetts Institute of Technology (MIT), Cambridge, MA, USA.ORCID http://orcid.org/0000-0002-6702-4192
H Charles ManningDepartment of Radiology and Radiological Sciences, VUMC, Nashville, TN, USA.
Jeffrey C RathmellDepartment of Pathology, Microbiology and Immunology, VUMC, Nashville, TN, USA. jeff.rathmell@vumc.org.ORCID http://orcid.org/0000-0002-4106-3396
W Kimryn RathmellDepartment of Medicine, Vanderbilt University Medical Center (VUMC), Nashville, TN, USA. kimryn.rathmell@vumc.org.ORCID http://orcid.org/0000-0002-4984-0225
Vanderbilt University · USVanderbilt University Medical Center · USBroad Institute · USValley Health System · USUniversity of Chicago · USWhitehead Institute for Biomedical Research · US
Funding
Tumor Immunology and Microenvironment Research ProgramP30CA068485 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MATTHEW J TYSKA · 1995 to 2026
$172.8MVIRUS PRODUCTION COREP30CA014051 · NCI · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · PI Darrell J Irvine · 1985 to 2026
$93.9MMedical Scientist Training ProgramT32GM007753 · NIGMS · HARVARD UNIVERSITY (MEDICAL SCHOOL) · PI WALENSKY, LOREN DAVID · 1985 to 2021
$50.0MVANDERBILT UNIVERSITY CTSA FOR PEDIATRIC RESEARCHUL1RR024975 · NCRR · VANDERBILT UNIVERSITY · PI BERNARD, GORDON RAPHAEL · 2007 to 2011
$45.7MTranslational Analysis CoreP30DK058404 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RICHARD M. PEEK · 2002 to 2026
$29.9MMEDICAL SCIENTIST TRAINING PROGRAMT32GM007347 · NIGMS · VANDERBILT UNIVERSITY · PI WILLIAMS, CHRISTOPHER S. · 1985 to 2023
$26.3MVanderbilt-Ingram Cancer Center SPORE in Gastrointestinal CancerP50CA236733 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI STEPHEN W. FESIK · 2019 to 2026
$19.6MShop Module CoreP30EY008126 · NEI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Kevin L Schey · 1989 to 2026
$19.6MVanderbilt Clinical Oncology Research Career Development ProgramK12CA090625 · NCI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Debra L. Friedman, Paula Jill Hurley · 2001 to 2026
$16.9MVanderbilt Mouse Metabolic Physiology CenterU24DK059637 · NIDDK · VANDERBILT UNIVERSITY · PI WASSERMAN, DAVID H · 2001 to 2015
$14.9MVANTAGE:Consolidation to create the Vanderbilt Technologies for Advanced GenomicsG20RR030956 · NCRR · VANDERBILT UNIVERSITY · PI PIETENPOL, JENNIFER A · 2010 to 2010
$8.7MVanderbilt O'Brien Kidney Center - Core D - Clinical and Translational CoreP30DK114809 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI WILSON, MATTHEW H · 2017 to 2021
$5.9MBLRD VA I01 BX000320BLRD VA I01 BX001426BLRD VA IK2 BX004585BLRD VA IS1 BX003154NCI NIH HHS F30 CA239367NCI NIH HHS F30 CA247202NCI NIH HHS K00 CA234920NCI NIH HHS K12 CA090625NCI NIH HHS P30 CA014051NCI NIH HHS P30 CA068485NCI NIH HHS P50 CA236733NCI NIH HHS R01 CA217987NCI NIH HHS R35 CA242379NCRR NIH HHS G20 RR030956NCRR NIH HHS UL1 RR024975NEI NIH HHS P30 EY008126NIDDK NIH HHS F30 DK120149NIDDK NIH HHS P30 DK058404NIDDK NIH HHS P30 DK114809NIDDK NIH HHS R01 DK105550NIDDK NIH HHS U24 DK059637NIGMS NIH HHS T32 GM007347NIGMS NIH HHS T32 GM007753NIGMS NIH HHS T32 GM152284NIH HHS S10 OD016245NIH HHS S10 OD019963NIH HHS S10 OD023475
Abstract
Cancer cells characteristically consume glucose through Warburg metabolism
Indexed as
Tumor MicroenvironmentAnimalsCarcinoma, Renal CellCell Line, TumorFemaleGlucoseGlutamineHumansLipid MetabolismMaleMechanistic Target of Rapamycin Complex 1MiceMyeloid CellsNeoplasmsNutrientsGlucoseGlutamineMechanistic Target of Rapamycin Complex 1Nutrients
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.